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Available online at www.sciencedirect.comPersistent viral infections, inflammatory syndromes and ageing
all induce the accumulation of highly differentiated CD45RA re-
expressing memory T cells. These cells increase during ageing,
especially in individuals who are infected with cytomegalovirus
(CMV). These cells have decreased proliferative capacity,
increased activation of senescence signalling pathways and
greater susceptibility to apoptosis in vitro. However these cells
are capable of multiple effector functions and thus bear all the
hallmarks of short-lived effector T cells. This indicates that
senescence signalling may govern the unique characteristics of
effector T cells. In this article, we address the functional and
migratory properties of these T cells and mechanisms that are
involved in their generation. Finally we assess the potential for
manipulation of their activity and whether this may improve
immune function during ageing.
Address
Division of Infection and Immunity, University College London,
5 University Street, London, WC1E 6JF, UK
Corresponding authors: Henson, Sian M (s.henson@ucl.ac.uk), Akbar,
Arne N (a.akbar@ucl.ac.uk)
a SMH and NER contributed equally to this work.
Current Opinion in Immunology 2012, 24:476–481
This review comes from a themed issue on Immune senescence
Edited by Arne Akbar and Richard Hodes
For a complete overview see the Issue and the Editorial
Available online 1st May 2012
0952-7915/$ – see front matter, # 2012 Elsevier Ltd. All rights
reserved.
http://dx.doi.org/10.1016/j.coi.2012.04.001
Introduction
CD45, the leukocyte common antigen is a glycoprotein
that constitutes much of the cell surface of lymphocytes
[1,2]. Multiple isoforms of this molecule have been ident-
ified and these are differentially expressed depending on
cell type and activation status [2]. The large cytoplasmic
domain of this molecule has protein tyrosine phosphatase
activity [3]. The different CD45 isoforms are generated by
alternate splicing [4] from exons 4, 5 and 6, generating
CD45RA, RB and RC respectively [2]. It is now recognized
that naive T lymphocytes express the high molecular
weight isoform containing the A exon (CD45RA) and that
is lost after activation and replaced by the low molecular
weight isoform CD45RO [5]. Therefore CD45RA expres-
sing T cells were initially considered to be naı¨ve T cellsCurrent Opinion in Immunology 2012, 24:476–481 that were the precursors of CD45RO+ T cells that con-
tained the primed/memory T cell pool [5]. However the
division of T cells into CD45RA+ naı¨ve and CD45RO+
memory T cells was found to be an oversimplification, as
human T cells can revert from CD45RO+ to CD45RA+ in
vivo [6–8], and in vitro [9,10].
Highly differentiated CD45RA re-expressing T cells
within both the CD4 and CD8 compartments increase
considerably during ageing and after CMV infection [11–
14]. Numerous reports have suggested that these cells
have characteristics of end stage differentiation [15–17].
However more recent studies have shown that they can
be reactivated to proliferate when provided with appro-
priate co-stimulatory signals [18,19,20]. In this article
we question the relevance of highly differentiated
CD45RA re-expressing T cells to immunity in general,
the signalling processes that may govern their end-stage
characteristics, and whether the functions of these cells
are altered during ageing.
Primed CD45RA re-expressing T cells have
end-stage characteristics
The process of repeated T cell stimulation that leads to
differentiation may also result in a loss of replicative
capacity as a consequence of telomere erosion and/or
unrepaired DNA damage [21,22]. Both processes engage
a complex set of proteins involved in DNA repair [23]. If
the perceived damaged DNA is not rectified, then growth
arrest mediated by active cell signalling ensues [21,22].
There are a number of similarities between the senes-
cence induced growth arrest in fibroblasts in and human T
cells. For example signalling through the mitogen-acti-
vated protein kinase p38 MAP kinase and p53 occurs and
the cyclin-dependent kinase inhibitors p16 and p21 [21]
are involved in both cell types. However differences in
senescence between these cells include the fact that
senescent fibroblasts are viable but non-proliferative
[24] whereas end stage T cells are highly susceptible
to apoptosis [13] but may persist in vivo in the presence of
appropriate survival signals [21]. Indeed, analysis of deut-
erated glucose uptake in proliferating T cells indicates
that CD45RA re-expressing memory CD8+ T cells in
older individuals persist owing to a reduced rate of cell
death and not accelerated proliferation in vivo [25].
Another difference is that fibroblasts do not upregulate
the enzyme telomerase, which can add-back telomeres
and compensate for telomere loss, whereas human T cells
are able to do so [26,27]. It has been shown that CD45RA
re-expressing T cells lose the ability to induce thiswww.sciencedirect.com
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Migratory potential of CD45RA re-expressing T cells. The migratory
marker expression of human CD45RA re-expressing T cells indicates
their propensity for peripheral and inflamed tissues and not the lymph
nodes. However human CD45RA re-expressing T cells are not strictly
exiles from lymphoid organs as large amount of these cells are also
found in the bone marrow and spleen.enzyme and this contributes to their senescence
[20,28,29].
T cell differentiation can be defined using the relative
levels of expression of CD27, CD28 and CD45RA
[17,21,30,31], with highly differentiated end-stage T cells
being CD45RA+CD27CD28. These end-stage T cells
also express increased surface inhibitory receptors such as
KLRG1 [19] and CD57 [17,21,30,31]. CD45RA+
CD27CD28 T cells within both the CD4 and CD8
compartments also exhibit an increase in DNA damage
visualized by phosphorylated H2AX (gH2AX), a member
of the histone H2A family that is phosphorylated in
response to double-strand breaks [23]. In addition,
highly differentiated human T cells within both CD4
and CD8 compartments have altered signalling pathways
including defective Akt (PKB) ser473 phosphorylation
[13,29] and increased p38 MAP kinase signalling [20]
and both these alterations may contribute to the defective
telomerase activity in these cells [20,29].
The loss of telomeric repeats is another way of assessing
T cell differentiation [26] and initial studies indicated
that highly differentiated CD8+ T cells that re-express
CD45RA had the shortest telomeres [31,32]. However
studies using larger numbers of donors showed that
CD45RA+CD27 T cells have relatively long telomeres
compared to the CD45RACD27 effector memory T
cells but shorter telomeres than naı¨ve and central memory
populations in both CD4+ and CD8+ compartments
[20,28]. Therefore CD45RA+ re-expressing T cells have
multiple signatures of senescence and end-stage differ-
entiation however these characteristics are not totally
dependent on telomere erosion [21].
Primed CD45RA re-expressing T cells are a
potent effector population
It has been shown that primed CD4 and CD8 T cells that
re-express CD45RA can secrete multiple cytokines in-
cluding IFN-g and TNF-a and exhibit potent cytotoxic
activity after activation [9,13,16]. However these cells
have reduced capacity to secrete IL-2 [30,32]. This has
been demonstrated for total T cells as well as populations
that are specific for Epstein Barr virus [33] as well as
cytomegalovirus [11,12,34]. Although these cells accumu-
late in older humans [11,13,14] it is not clear if these cells
are fully functional since some reports show that CMV
specific T cells have reduced capacity to synthesize IFN-
g [35]. The majority of studies of CD45RA re-expressing
T cells have been performed with peripheral blood popu-
lations. However an important observation is that
although these cells have poor proliferative activity they
can be activated and proliferate if provided with appro-
priate co-stimulatory signals or accessory populations
[9,29]. Once activated, these cells can mediate potent
effector function but die rapidly [13]. This cell population
may therefore have a role as a sentinel population ofwww.sciencedirect.com effector cells that patrol sites of frequent antigenic
encounter. However the effector properties of these cells
suggest that they may have a role in other tissues and it is
therefore important to assess their migratory potential.
Migratory potential of CD45RA re-expressing
T cells
The effectiveness of a T cell is closely related to its
propensity to migrate to particular organs and tissues
[36,37]. Naı¨ve and central memory cells have a propensity
to home to draining lymph nodes (LN) where dendritic
cells can present cognate antigen from the site of infection
[36–38] while effector memory cells require entry into
peripheral tissues where they induce pathogen clearance
through cytokine secretion and cytotoxic activity [36].
The chemokine receptors CXCR4, CCR7 and CD62L
that are expressed by naı¨ve and central memory T cells
facilitate their migration into LNs [37,39]. CD45RA re-
expressing memory T cells do not express these four
homing receptors that strongly suggest an inability of the
population to migrate into LN (Figure 1). Indeed, cyto-
megalovirus (CMV)-specific CD8+ T cells that express
CD45RA are absent from the LN of humans despite
being present at high percentages in the peripheral blood
[40]. Instead, CD45RA re-expressing memory T cells
constitutively express receptors that direct their
migration to peripheral and/or inflamed tissue. These
include high levels of CX3CR1, which binds fraktalkineCurrent Opinion in Immunology 2012, 24:476–481
478 Immune senescencethat is expressed by stressed endothelium, thus allowing
entry into inflamed vascular endothelium [41]; high levels
of CD11a or CD18, the components of LFA-1 that
facilitates recruitment to infection sites by binding
ICAM-1; and CD49e that allows interaction with extra-
cellular matrix [42]. Upon stimulation with cognate
antigen, CD45RA re-expressing memory T cells also
upregulate other inflammation associated adhesion mar-
kers, such as CCR5 that binds RANTES or macrophage
inflammatory proteins (MIP) that are both expressed by
inflamed tissue [12]. CD45RA re-expressing memory T
cells are also found in human spleen and bone marrow
(BM) [13,43,44,45].
Collectively the available data suggest that although
CD45A re-expressing T cells are highly differentiated,
close to senescence and have low proliferative capacity,
they migrate preferentially to sites of inflammation where
they may exert their potent effector activity [42]. How-
ever it is also possible that the spleen and bone marrow may
be sites where these cells are generated (Figure 1) [13].
CD45RA re-expressing T cells may
accumulate via antigen-independent cytokine
driven homeostasis
Memory T cells are maintained by and can differentiate
in response to both antigen activation and homeostatic
cytokine stimulation [36]. It is unlikely that CD45RA re-
expressing memory cells have experienced a recent
encounter with antigen since TCR ligation induces
CD45RO expression both in vitro and during primary
responses in vivo [12,15,46,47]. However after resol-
ution of a primary infection with Epstein-Barr virus
(EBV) some antigen specific T cells express CD45RA
[8]. In addition, CD45RA+ re-expressing CD8+ T cells
were found to be the dominant (quiescent) memory
population that was generated following vaccination
against yellow fever despite the fact that these cells were
CD45RO+ initially [47]. This highlights that CD45RA
re-expressing memory cells may arise without the
requirement of repeated antigen exposure, since these
individuals were only vaccinated once, and can survive in
vivo in the absence of antigen [47].
It has been shown that CD45RA re-expressing memory
cells can be generated from the CD45RO population of T
cells by the addition of the homeostatic cytokines IL-7
and IL-15, in the absence of antigen in vitro [9,10,13,15].
Isolated EBV-specific CD8+ T cells that were CD45RO+
could be induced to re-express CD45RA by incubation
with IL-15, and these cells exhibited potent cytotoxic
activity against EBV infected target cells [9]. Further-
more, IL-15 injections can induce massive expansions of
CCR7CD28CD8+ memory T cells in rhesus macaques
[48] however it is not clear if these cells are equivalent to
the CD45RA re-expressing T cells in humans as reagents
to this molecule is not available in these primates. ItCurrent Opinion in Immunology 2012, 24:476–481 would therefore be predicted that these cells may be
generated in tissues that contain large amounts of homeo-
static cytokines or cytokine producing cells [49,50]. This
is supported by the observation that CD4+
CD45RA+CD27T cells of different antigen specificities
were found at significantly higher proportions in the bone
marrow, a recognized site of IL-7 production [51], com-
pared to the blood of the same individuals [13]. Finally,
the fact that IL-15 stimulation can maintain human
memory cells without telomere erosion in vitro may
explain how CD8+CD45RA re-expressing memory cells
become highly differentiated without chronic reduction
in telomere length in vivo [52], since these cytokines can
induce telomerase activity [52,53]. Important but unan-
swered questions are whether these cytokines engage
senescence signalling pathways in the cells that re-
express CD45RA and whether the CD45RA molecule
itself is essential for the function of these cells. Further-
more since large populations of CD45RA re-expressing T
cells dominate the T cell compartment of older humans,
the role of homeostatic proliferation in shaping the T cell
repertoire during ageing has to be addressed.
Can T cell senescence be reversed?
The data that have been discussed above indicates that
CD45RA re-expressing T cells exhibit characteristics of
senescence. However, these characteristics of senescence
are maintained by multiple distinct signalling processes
and some of these changes are reversible. For example, as
T cells differentiate they lose the expression of the sur-
face co-stimulatory molecule CD28, which may result in
some of the functional changes in highly differentiated
populations [27,54]. However, the induction of CD28 re-
expression or the ligation of alternative co-stimulatory
molecules such as ICOS, CD137 and CD134, enhance the
proliferation [18,29] in certain subsets of CD8+CD28T
cells [29]. Highly differentiated T cells also express
multiple inhibitory receptors [55]. The defective prolifer-
ation of these cells can be reversed by blockade of
KLRG1 and PD-1 signalling, which induces AKT
Ser473 phosphorylation that is defective in these cells
[19,56]. However, neither the blockade of KLRG1 or
PD-1 signalling reverses the telomerase defect in these
cells [19,56].
By contrast, it has been shown that CD45RA re-expres-
sing CD4+ T cells have increased expression of both total
and phosphorylated forms of p38 MAP kinase, that is
involved in the senescence process in fibroblasts
[57,58]. The inhibition of p38 signalling using a specific
inhibitor in CD45RA+CD27CD4+ T cells significantly
enhanced the proliferation, telomerase activity and sur-
vival of these cells after TCR activation [20]. Similar
observations have also been made in CD8+
CD45RA+CD27 T cells (Henson and Akbar, unpub-
lished observations). An additional way to reverse senes-
cence in human T cells is by transducing these cells withwww.sciencedirect.com
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Potential routes for functional manipulation of CD45RA re-expressing T cells. CD45RA re-expressing T cells display both proliferative and signalling
defects but remain highly polyfunctional, is it therefore possible to enhance immunity by boosting the function of CD45RA re-expressing T cells.
Potential avenues for manipulating function include replacing lost co-stimulatory molecules, such as CD28 or TNF family members or blocking
inhibitory receptor signalling. Intervention may be targeted at either the prevention of CMV replication by vaccination or anti-viral therapy or the
removal of CMV-specific cells. Finally DNA damage response could be manipulated, such as blockade of p53 or p38 MAPK signalling.hTERT, the catalytic component of telomerase and
many laboratories have achieved this goal [59]. Alterna-
tively, the activity of this enzyme can be enhanced using
ERK kinase activators [60].
Although there are ways available to reverse T cell senes-
cence the key questions that arise are whether senescence
restricts immune function in older humans in the first place
and second whether it is safe to do so. Highly differentiated
CD45RA re-expressing T cells have been shown to
accumulate in older adults [27,28] patients with persistent
viral infections [11,16,61] and those with inflammatory
syndromes such as rheumatoid arthritis [42,62]. As T cell
function is reduced in patients with chronic viral infections
and in older adults [35], it raises the possibility that
enhancement of function of the CD45RA re-expressing
population may boost immunity (Figure 2). However the
reversal of senescence by enhancing telomerase by a
variety of ways has risks, since senescence-induced pro-
liferative arrest is considered to be a first line of defence
against cancer [22] and blocking this proliferative check-
point may pose the risk of propagating T cells with DNA
damage and thus malignancy. In addition reversal of the
proliferative defect in T cells by blocking p38 may lead to
decreased rather than increased effector functions as this
molecule is important for pro-inflammatory cytokine
secretion [20,63]. Ideally, the enhancement of immunity
during ageing would require a strategy that enhances the
function of T cells with minimal risk of malignancy or
inflammation. Although progress has been made about
how T cell function is constrained during differentiation
and ageing, the current state of expertise is somewhat shortwww.sciencedirect.com of this goal. Nevertheless since the proliferation of T cells
can be enhanced temporarily by p38 inhibition or by
blocking inhibitory receptors, this may be a way to boost
specific T cell populations intermittently, for example
during vaccination.
Conclusions
CD45RA re-expressing memory T cells display senes-
cence-related proliferative defects that are reversible. In
young individuals these cells are capable of efficient
cytokine secretion and cytotoxicity however it is not
completely clear if these cells lose effector function
during ageing. The CD45RA re-expressing T cells have
relatively long telomeres, suggesting that these cells are
governed by telomere-independent senescence. The
temporary reversal of proliferative defects in highly dif-
ferentiated T cells may be a way to increase specific T cell
numbers during vaccination, but long term reversal of
senescence carries the risk of malignancy.
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